![PDF] Integrin inhibitor cilengitide for the treatment of glioblastoma: a brief overview of current clinical results. | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/70bc1a06a730e1f512f80dac37d33d6c52a1670a/5-TableI-1.png "PDF] Integrin inhibitor cilengitide for the treatment of glioblastoma: a brief overview of current clinical results. | Semantic Scholar")
PDF] Integrin inhibitor cilengitide for the treatment of glioblastoma: a brief overview of current clinical results. | Semantic Scholar
NEWS RELEASE MDxHealth and Merck KGaA extend Agreement for use of MGMT Assay in Brain Cancer Clinical Trials
Cilengitide | C27H40N8O7 | CID 176873 - PubChem
Cilengitide
Frontiers | Cyclic RGD Pentapeptide Cilengitide Enhances Efficacy of Gefitinib on TGF-β1-Induced Epithelial-to-Mesenchymal Transition and Invasion in Human Non-Small Cell Lung Cancer Cells
Cilengitide: an RGD pentapeptide ανβ3 and ανβ5 integrin inhibitor in development for glioblastoma and other malignancies | Future Oncology
Cilengitide in patients with recurrent glioblastoma: the results of NABTC 03-02, a phase II trial with measures of treatment delivery | SpringerLink
cilengitide | Ligand page | IUPHAR/BPS Guide to PHARMACOLOGY
Cilengitide induces cellular detachment and apoptosis in endothelial and glioma cells mediated by inhibition of FAK/src/AKT pathway | Journal of Experimental & Clinical Cancer Research | Full Text
Cilengitide inhibits metastatic bone colonization in a nude rat model
Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial - The Lancet Oncology
Frontiers | Cyclic RGD Pentapeptide Cilengitide Enhances Efficacy of Gefitinib on TGF-β1-Induced Epithelial-to-Mesenchymal Transition and Invasion in Human Non-Small Cell Lung Cancer Cells
Cilengitide: the first anti-angiogenic small molecule drug candidate design, synthesis and clinical evaluation. - Abstract - Europe PMC
Cilengitide - Wikipedia
Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial - The Lancet Oncology
Emerging therapeutic opportunities for integrin inhibitors | Nature Reviews Drug Discovery
Full article: Cilengitide, an αvβ3-integrin inhibitor, enhances the efficacy of anti-programmed cell death-1 therapy in a murine melanoma model
Phase I & II Clinical Trials - Statistical Considerations - The University of Alabama at Birmingham
Integrin Inhibitor Cilengitide for the Treatment of Glioblastoma: A Brief Overview of Current Clinical Results | Anticancer Research
Iceni Pharmaceuticals Launches as New Specialist in Cancer Therapies
The Integrin Inhibitor Cilengitide and Bleomycin-Induced Pulmonary Fibrosis | SpringerLink
Pharmaceutics | Free Full-Text | Integrin-αvβ3 as a Therapeutic Target in Glioblastoma: Back to the Future?
Cilengitide (EMD 121974) | ανβ3/ανβ5/α5β1 Inhibitor | MedChemExpress
